The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...

Reaching participants through retail pharmacies, the study speaks to how much VHD goes underrecognized—with a few surprises.

The everolimus scaffold, which had mostly disappeared by 3 years, was still associated with fewer reinterventions than PTA.

Operators are excited about a device that avoids transapical access, a limitation of other systems, says Gilbert Tang.